Biomark Capital

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

BetterDoctor, Inc. is a company based in San Francisco, California, that specializes in developing web and mobile applications to assist users in finding healthcare providers. Founded in 2011, BetterDoctor allows users to specify the type of doctor they need and select their insurance plan to view a list of verified healthcare professionals. The company's platform provides accurate provider data to health plans, health systems, and various organizations through its API, facilitating the search for doctors and improving healthcare access. BetterDoctor's services have reached millions of users, powering numerous health plans and companies by enhancing the transparency and reliability of doctor data. As of June 2018, BetterDoctor operates as a subsidiary of Quest Analytics, L.L.C.

Eden Biologics, formerly known as JHL Biotech, is a biopharmaceutical company that specializes in the development of biosimilars and offers contract development and manufacturing services to various clients and partners. The company focuses on producing a diverse range of complex dosage forms, including oral solid, liquid, and semi-solid products, as well as macromolecule biologics. By leveraging its expertise in both global and regional regulatory affairs, Eden Biologics aims to make biopharmaceuticals more affordable and accessible to patients worldwide. Through its comprehensive services, the company supports the entire process from cell line development to commercial manufacturing, enhancing the efficiency and effectiveness of biopharmaceutical development for its partners.

i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients.

WhiteGlove Health, Inc. is a mobile healthcare provider based in Austin, Texas, specializing in delivering primary care, preventative medical services, and support for individuals with chronic conditions directly at home and work sites. Established in 2006, the company has expanded its services to major locations including Dallas/Fort Worth, Houston, San Antonio, and Phoenix. WhiteGlove Health focuses on creating a high-quality healthcare experience while simultaneously reducing costs for health plans through decreased insurance claims and minimized unnecessary medical utilization. The clinical team, composed of board-certified nurse practitioners and registered nurses, provides comprehensive care, including at-home visits and telephonic support, particularly for high-risk patients under Medicare and Medicaid. The company’s Value-Based Care division, launched in 2014, emphasizes proactive management to reduce hospital admissions and improve patient outcomes. Additionally, WhiteGlove Health enhances its service offerings through a partnership with Glenridge Healthcare Solutions, which provides advanced analytics and technology solutions, further promoting efficient healthcare delivery across the nation.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

HyperMed Imaging, Inc. specializes in developing advanced hyperspectral imaging technology for medical applications, specifically focusing on surface tissue oximetry solutions. Founded in 2006 and based in Memphis, Tennessee, the company has created the HyperView Imaging System, which provides crucial measurements of oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissues. Their flagship product, OxyVu, initially designed for the U.S. research market, has received FDA 510(k) approval for its use in medical diagnostics. This system aids physicians in assessing microvasculature perfusion, significantly contributing to patient care in areas such as wound healing, diabetic foot ulcers, and amputation planning. The clinical diagnostic applications of hyperspectral imaging represent a substantial market opportunity, estimated to be worth billions.

Flexible Stenting Solutions, Inc. is a privately held medical device company specializing in the design and commercialization of flexible stents. Utilizing a proprietary design platform, the company has developed a third-generation self-expanding stent tailored for challenging conditions in the superficial femoral and popliteal arteries. This innovative stent boasts enhanced durability, fatigue resistance, superior radial stiffness, and a low chronic outward force, achieved through the integration of helically wound struts and flexible coils. The delivery technology prioritizes simplicity and ease of placement. Flexible Stenting Solutions has received CE Mark authorization for its FlexStent® Femoropopliteal and Biliary Self Expanding Stent Systems, as well as 510(k) clearance for its Biliary Self Expanding Stent System, which aims to alleviate symptoms associated with malignant biliary strictures.

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

Spectral Image, Inc. is an early-stage medical device company based in Tampa, Florida, founded in 2007. The company specializes in the development of advanced imaging technology for biomedical applications. Currently operating in stealth mode, Spectral Image is not publicly disclosing specific details about its technology until it secures the necessary intellectual property rights. In 2008, the company plans to initiate a pilot study at a leading medical facility to further validate its innovations. GBP Capital serves as the sole investor for Spectral Image, supporting its mission to enhance medical imaging capabilities.